Foundation Medicine has struck a deal with Johnson & Johnson Pharmaceutical Research and Development to use Foundation's targeted sequencing cancer test to identify potential biomarkers that could be of interest for the pharmaceutical company's clinical oncology programs.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Foundation Medicine today said that it will partner with Johnson & Johnson Pharmaceutical Research and Development in a biomarker identification collaboration.
FDA Commissioner Margaret Hamburg has hired Steven Spielberg, director of the Center for Personalized Medicine and Therapeutic Innovation at Children’s Mercy Hospital in Kansas City, for the newly created position of deputy commissioner for medical products and tobacco.
In recent interviews, J&J officials spoke about ongoing work to further develop its technology for circulating tumor cells to include characterization capabilities, and its new center of excellence for companion diagnostics to leverage partnerships with other diagnostic firms.
Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.